Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LeonaBio ( (LONA) ) has provided an update.
At a recent special meeting, LeonaBio stockholders approved the 2026 Equity Incentive Plan, replacing the 2020 plan for new grants while preserving existing awards, and authorizing up to 5.7 million new shares plus up to 1.3 million returning shares, with future annual increases tied to outstanding equity. Standardized option, restricted stock, and RSU agreements will govern grants under the new plan, reinforcing the company’s ability to recruit and retain key personnel.
Shareholders also cleared several capital-related measures, including approvals for the issuance of 5,502,402 shares on exercise of a Sermonix pre-funded warrant and for additional issuances to Sermonix and Perceptive Advisors above the 19.99% ownership threshold under Nasdaq rules. On March 18, 2026, LeonaBio implemented an amendment to its certificate of incorporation, raising authorized common shares from 90 million to 400 million and total authorized capital stock from 190 million to 500 million, materially expanding its capacity for future financings and strategic transactions.
The most recent analyst rating on (LONA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on LeonaBio stock, see the LONA Stock Forecast page.
Spark’s Take on LONA Stock
According to Spark, TipRanks’ AI Analyst, LONA is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, sustained losses, and ongoing cash burn), partially offset by low leverage. Technicals also weigh on the score due to a weak trend (below key moving averages) and negative momentum indicators, while valuation provides limited support given a negative P/E and no dividend.
To see Spark’s full report on LONA stock, click here.
More about LeonaBio
LeonaBio, Inc. operates in the life sciences sector and uses equity incentive plans to attract and retain employees, directors, and consultants through stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards. The company is listed on Nasdaq and actively manages its capital structure, including common stock, pre-funded warrants, and preferred stock, to support financing and strategic partnerships.
Average Trading Volume: 92,174
Technical Sentiment Signal: Buy
Current Market Cap: $91.31M
Find detailed analytics on LONA stock on TipRanks’ Stock Analysis page.